| FC N (%) | FCF N (%) | Crude OR (95 % CI) P-value | Adjusted ORa (95 % CI) P-value | Adjusted ORb (95 % CI) P-value |
---|---|---|---|---|---|
 | (N = 149) | (N = 398) |  |  |  |
1Â month follow-up | Â | Â | Â | Â | Â |
 7-day point prevalence | 24 (16.1) | 74 (18.6) | 1.19 (0.72–1.97) 0.50 | 1.02 (0.60–1.73) 0.94 | 1.05 (0.60–1.85) 0.86 |
3Â month follow-up | Â | Â | Â | Â | Â |
 7-day point prevalence | 26 (17.4) | 92 (23.1) | 1.42 (0.88–2.31) 0.15 | 1.30 (0.79–2.14) 0.31 | 1.35 (0.79–2.31) 0.27 |
 1 month continuous abstinence | 23 (15.4) | 73 (18.3) | 1.23 (0.74–2.05) 0.43 | 1.11 (0.65–1.88) 0.71 | 1.17 (0.67–2.05) 0.59 |
6Â month follow-up | Â | Â | Â | Â | Â |
 7-day point prevalence | 24 (16.1) | 103 (25.9) | 1.82 (1.11–2.97) 0.02 | 1.70 (1.03–2.82) 0.04 | 1.92 (1.12–3.32) 0.02 |
 1 month continuous abstinence | 23 (15.4) | 95 (23.9) | 1.72 (1.04–2.83) 0.03 | 1.64 (0.98–2.74) 0.06 | 1.82 (1.05–3.16) 0.03 |
 3 month continuous abstinence | 22 (14.8) | 77 (19.3) | 1.39 (0.83–2.32) 0.22 | 1.31 (0.77–2.24) 0.32 | 1.48 (0.83–2.62) 0.19 |
12Â month follow-up | Â | Â | Â | Â | Â |
 7-day point prevalence | 22 (14.8) | 105 (26.4) | 2.07 (1.25–3.43) 0.005 | 2.08 (1.24–3.50) 0.006 | 2.34 (1.34–4.10) 0.003 |
 6 month continuous abstinence | 16 (10.7) | 78 (19.6) | 2.03 (1.14–3.60) 0.02 | 2.14 (1.19–3.88) 0.01 | 2.41 (1.28–4.52) 0.006 |